AMSBIO announces the launch of StemFit® Basic03 clinical grade stem cell culture for regenerative medicine.

Provided as a animal-origin free, ready to use media for cell therapy applications, StemFit® AK03N which is the Japanese version of Basic03 has already been accepted by Pharmaceuticals and Medical Devices Agency, Japan (PMDA) for retinal regenerative medicine clinical trials using human induced pluripotent stem cells (hiPSCs).

In an independent study**, media of different formulations were compared with StemFit® Basic03 for culturing iPS cells. The resultant research data showed, iPS cells cultured with StemFit® Basic03 offered higher cell proliferation, lower lactate accumulation and demonstrated better homogeneity of gene expression compared with iPS cells cultured with 4 other media.

Completely free of animal- and human-derived components StemFit® Basic03 is proven to provide highly stable and reproducible culture condition for Induced Pluripotent Stem and Embryonic Stem cells under feeder-free conditions during the reprogramming, expansion and differentiation phases of stem cell culture. StemFit® Basic03 combines high colony forming efficiency with lower than standard media volume consumption to offer cost effective colony expansion when compared to leading competitors.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

more news from amsbio